TGTX

TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027.

IDEXX Laboratories is set to report Q3 2026 results on November 2, with consensus estimates projecting 7.5% revenue growth to $1.19 billion and 9.1% EPS growth to $3.71. The company's Companion Animal Group diagnostics, Water segment, and Livestock/Poultry/Dairy divisions are expected to drive performance, supported by volume growth and recurring revenues. IDEXX carries a Zacks Rank #2 with a +0.59% Earnings ESP, suggesting potential to beat estimates.

Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.